Hutch News

Hutch News

Stories tagged 'Ovarian Cancer'

Good News at Fred Hutch

Celebrating faculty and staff achievements

Sept. 14, 2017

An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

View story >


How cancer fools healthy neighboring cells

‘Tumor microenvironment’ research underscores why we need cancer immunotherapy — and how to make it work for more patients

July 18, 2017 | By Rachel Tompa / Fred Hutch News Service

Like tiny con men, cancer cells have many tricks to fool healthy cells into helping them. Research into the "tumor microenvironment" is uncovering new avenues for treatment.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

June 29, 2017

Dr. Amanda Paulovich of Fred Hutch has been selected to lead a multi-institution effort to develop a biological test to predict which treatments will work for patients with ovarian cancer.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

May 12, 2017 | By Kristen Woodward / Fred Hutch News Service

Eight Fred Hutch/University of Washington researchers receive pilot awards that support a range of innovative concepts with the potential to improve cancer patients' lives.

View story >


Dissolving implant could bring immunotherapy to solid tumors

A biopolymer sponge delivers cancer-shrinking T-cell therapy in preclinical study

April 24, 2017 | By Sabrina Richards / Fred Hutch News Service

A dissolving scaffold developed by Dr. Matthias Stephan delivers engineered anti-tumor immune cells to crowded masses of tumor cells and recruits the native immune system to mount a second-wave attack on the cancer.

View story >


Immunotherapy for ovarian cancer shows promise in mouse model, but hurdles remain

‘Tumor microenvironment’ poses unique challenges for T-cell therapy in solid tumors

April 4, 2017 | By Rachel Tompa / Fred Hutch News Service

A major roadblock to adopting T-cell therapy to solid tumors is what’s known as the tumor microenvironment, the local milieu of non-cancerous cells and molecules in and around the tumor. Fred Hutch researcher Dr. Kristin Anderson and her colleagues in Dr. Phil Greenberg's lab are working to overcome those barriers.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.